Literature DB >> 26794864

Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs.

Ignazio Olivieri1, Salvatore D'Angelo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26794864     DOI： 10.1038/nrrheum.2015.184

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

Authors:  Laura C Coates; Anna R Moverley; Lucy McParland; Sarah Brown; Nuria Navarro-Coy; John L O'Dwyer; David M Meads; Paul Emery; Philip G Conaghan; Philip S Helliwell
Journal:  Lancet       Date:  2015-10-01       Impact factor: 79.321

2.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

Authors:  Philip J Mease; Iain B McInnes; Bruce Kirkham; Arthur Kavanaugh; Proton Rahman; Désirée van der Heijde; Robert Landewé; Peter Nash; Luminita Pricop; Jiacheng Yuan; Hanno B Richards; Shephard Mpofu
Journal:  N Engl J Med       Date:  2015-10       Impact factor: 91.245

3.  Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.

Authors:  Laura C Coates; Philip S Helliwell
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

4.  Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.

Authors:  Muhammad Haroon; Phil Gallagher; Oliver FitzGerald
Journal:  Ann Rheum Dis       Date:  2014-02-13       Impact factor: 19.103

Review 5.  Advances in the management of psoriatic arthritis.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Carlo Palazzi; Angela Padula
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

6.  EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice.

Authors:  P Mandl; V Navarro-Compán; L Terslev; P Aegerter; D van der Heijde; M A D'Agostino; X Baraliakos; S J Pedersen; A G Jurik; E Naredo; C Schueller-Weidekamm; U Weber; M C Wick; P A C Bakker; E Filippucci; P G Conaghan; M Rudwaleit; G Schett; J Sieper; S Tarp; H Marzo-Ortega; M Østergaard
Journal:  Ann Rheum Dis       Date:  2015-04-02       Impact factor: 19.103

7.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Iain B McInnes; Philip J Mease; Bruce Kirkham; Arthur Kavanaugh; Christopher T Ritchlin; Proton Rahman; Désirée van der Heijde; Robert Landewé; Philip G Conaghan; Alice B Gottlieb; Hanno Richards; Luminita Pricop; Gregory Ligozio; Manmath Patekar; Shephard Mpofu
Journal:  Lancet       Date:  2015-06-28       Impact factor: 79.321

8.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.

Authors:  Josef S Smolen; Jürgen Braun; Maxime Dougados; Paul Emery; Oliver Fitzgerald; Philip Helliwell; Arthur Kavanaugh; Tore K Kvien; Robert Landewé; Thomas Luger; Philip Mease; Ignazio Olivieri; John Reveille; Christopher Ritchlin; Martin Rudwaleit; Monika Schoels; Joachim Sieper; Martinus de Wit; Xenofon Baraliakos; Neil Betteridge; Ruben Burgos-Vargas; Eduardo Collantes-Estevez; Atul Deodhar; Dirk Elewaut; Laure Gossec; Merryn Jongkees; Mara Maccarone; Kurt Redlich; Filip van den Bosch; James Cheng-Chung Wei; Kevin Winthrop; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-06-08       Impact factor: 19.103

9.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Authors:  Christopher Ritchlin; Proton Rahman; Arthur Kavanaugh; Iain B McInnes; Lluis Puig; Shu Li; Yuhua Wang; Yaung-Kaung Shen; Mittie K Doyle; Alan M Mendelsohn; Alice B Gottlieb
Journal:  Ann Rheum Dis       Date:  2014-01-30       Impact factor: 19.103

10.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Authors:  Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett
Journal:  Ann Rheum Dis       Date:  2014-03-04       Impact factor: 19.103
  10 in total
  2 in total

1.  Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype.

Authors:  Antonio Marchesoni
Journal:  Rheumatol Ther       Date:  2018-06-01

Review 2.  Dermatologists' Role in the Early Diagnosis of Psoriatic Arthritis: Expert Recommendations.

Authors:  I Belinchón; L Salgado-Boquete; A López-Ferrer; M Ferran; P Coto-Segura; R Rivera; D Vidal; L Rodríguez; P de la Cueva; R Queiro
Journal:  Actas Dermosifiliogr (Engl Ed)       Date:  2020-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.